Business
Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on
About this update from Sensei Biotherapeutics, Inc.
[{"type":"text","content":"- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy - - Pre-registration available for live event, to be held Tuesday, June 27, 2023 at 2:00 p.m. ET - BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will host a virtual KOL event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors,” on Tuesday, June 27, 2023 at 2:00 p.m. ET. The event will feature James Gulley, M.D., Ph.D., Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI), who will provide an overview of the unmet medical need in solid tumors and the current immuno-oncology treatment landscape, and discuss the potential for Sensei’s lead candidate, SNS-101, a conditionally active VISTA-blocking antibody, to improve treatment outcomes for patients with solid tumors. Sensei management will provide insight into the preclinical mechanism and profile of SNS-101, and present an overview of the SNS-101 clinical program, including collaborating with the NCI as a site for the Phase 1/2 SNS-101 clinical trial. Sensei recently announced that the first patient has been dosed in the trial at a starting dose of 0.3 mg/kg. Participants may register in advance for the event online. A recording of the presentation will be made available on the Sensei website following the event. The event will conclude with a live Q&A session. If you would like to ask a question during the live Q&A, please submit your request to [email protected]. James Gulley, M.D., Ph.D., FACP, is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the National Cancer Institute (NCI). These innovative, investigator-initiated studies involve the use of cancer immunotherapy to (a) initiate immune responses, (b) expand immune responses and/or (c) allow the immune responses to be effective within the tumor microenvironment. In addition to his role as the CIO Co-Direc...